Determinants of pegivirus persistence, cross-species infection, and adaptation in the laboratory mouse.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
Aug 2024
Historique:
received: 18 04 2024
accepted: 22 07 2024
medline: 29 8 2024
pubmed: 29 8 2024
entrez: 28 8 2024
Statut: epublish

Résumé

Viruses capable of causing persistent infection have developed sophisticated mechanisms for evading host immunity, and understanding these processes can reveal novel features of the host immune system. One such virus, human pegivirus (HPgV), infects ~15% of the global human population, but little is known about its biology beyond the fact that it does not cause overt disease. We passaged a pegivirus isolate of feral brown rats (RPgV) in immunodeficient laboratory mice to develop a mouse-adapted virus (maPgV) that established persistent high-titer infection in a majority of wild-type laboratory mice. maRPgV viremia was detected in the blood of mice for >300 days without apparent disease, closely recapitulating the hallmarks of HPgV infection in humans. We found a pro-viral role for type-I interferon in chronic infection; a lack of PD-1-mediated tolerance to PgV infection; and multiple mechanisms by which PgV immunity can be achieved by an immunocompetent host. These data indicate that the PgV immune evasion strategy has aspects that are both common and unique among persistent viral infections. The creation of maPgV represents the first PgV infection model in wild-type mice, thus opening the entire toolkit of the mouse host to enable further investigation of this persistent RNA virus infections.

Identifiants

pubmed: 39196893
doi: 10.1371/journal.ppat.1012436
pii: PPATHOGENS-D-24-00650
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1012436

Informations de copyright

Copyright: © 2024 Nennig et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

David O’Connor is a founder of Pathogenuity LLC. All other authors have no competing interests to disclose.

Auteurs

Kylie Nennig (K)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Satyapramod Murthy (S)

Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.

Sara Maloney (S)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Teressa M Shaw (TM)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Mark Sharobim (M)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Eduard Matkovic (E)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Simi Fadiran (S)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Malorie Larsen (M)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Mitchell D Ramuta (MD)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Arthur S Kim (AS)

Department of Immunology and Microbiology, The Scripps Research Institute, San Diego, California, United States of America.
Department of Chemistry, The Scripps Research Institute, San Diego, California, United States of America.

John R Teijaro (JR)

Department of Immunology and Microbiology, The Scripps Research Institute, San Diego, California, United States of America.

Joe Grove (J)

MRC-University of Glasgow Center for Virus Research, Glasgow, United Kingdom.

Matthew Stremlau (M)

Brain Science Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America.

Himanshu Sharma (H)

Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.

Sheetal Trivedi (S)

Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.

Michael J Blum (MJ)

Department of Ecology & Evolutionary Biology, University of Tennessee, Knoxville, Tennessee, United States of America.

David H O'Connor (DH)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Jennifer L Hyde (JL)

Department of Microbiology, University of Washington, Seattle, Washington, United States of America.

Jack T Stapleton (JT)

Department of Internal Medicine, Microbiology & Immunology, University of Iowa and Iowa City Veterans Affairs Healthcare System, Iowa City, Iowa, United States of America.

Amit Kapoor (A)

Center for Vaccines and Immunity, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, United States of America.
Department of Pediatrics, College of Medicine and Public Health, Ohio State University, Columbus, Ohio, United States of America.

Adam L Bailey (AL)

Department of Pathology and Laboratory Medicine, University of Wisconsin-Madison School of Medicine and Public Health, Madison, Wisconsin, United States of America.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH